Abstract PS7-24: Characteristics of HR+/HER2- patients with recurrent disease by HER2 expression from a prospective registry of unresectable locally advanced or metastatic breast cancer: GEICAM/2014-03 (RegistEM)

Autor: César A. Rodríguez, Maria Jose Echarri, Isabel Alvarez, Carlos Poblete Jara, Federico Rojo, I Garau, Diana Moreno, Antonio Antón, Mireia Margeli, Josefina Cruz, Ariadna Tibau, M. J. Escudero, Purificación Martínez, Ángel L Guerrero, Silvia Antolín, Sara López-Tarruella, Catalina Falo, Marta Mori, Álvaro Rodríguez-Lescure, Susana Bezares

Publikováno v: Cancer Research. 81:PS7-24

Background: The RegistEM study is a non-interventional cohort study that will provide prospective data from >1,800 advanced breast cancer (ABC) patients (pts), either after recurrence or as first diagnosis in 38 Spanish sites. Primary objective is th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::136a5cb149a909a25006fca6e1b97a81
https://doi.org/10.1158/1538-7445.sabcs20-ps7-24

Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study

Autor: José Manuel Baena-Cañada, Jose Ignacio Chacon, Álvaro Rodríguez-Lescure, Miguel Martin, Manuel Ruiz-Borrego, Victoria Ruiz, Isabel Alvarez, Eva Carrasco, Angel Guerrero-Zotano, Josefina Cruz, M. J. Escudero, Montserrat Muñoz, Silvia Antolín, Elena Sevillano, Beatriz Cirauqui, Sonia Del Barco, Begoña Bermejo, Noelia Martínez-Jañez, Emilio Alba, Manuel Ramos, Antonio Antón

Publikováno v: Breast Cancer Research and Treatment. 177:115-125

GEICAM/2006–10 compared anastrozole (A) versus fulvestrant plus anastrozole (A + F) to test the hypothesis of whether a complete oestrogen blockade is superior to aromatase inhibitors alone in breast cancer patients receiving hormone adjuvant thera

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cb956078e467f5935f2f9f260e9a19d1
https://doi.org/10.1007/s10549-019-05296-8

Abstract GS2-04: Efficacy results from CIBOMA/2004-01_GEICAM/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer

Autor: Roberto Torres, P López-Álvarez, Carlos Sampaio, Carlos Barrios, E Villar, Eva Carrasco, A. Lluch, L Pérez-Michel, J.G.M. Segalla, S. Reyes, JA Garcia-Saenz, J. Cárdenas, Maria Jose Godes, M. Ramos, J Castellanos, A. Ruiz, M. J. Escudero, E Martínez de Dueñas, Lourdes Calvo, J Moncayo, J. M. Baena, Manuel Ruiz-Borrego, J. Vinholes, L Torrecillas, Susana Bezares, M. Martin, Henry L. Gomez, Agust Barnadas, M. A. Seguí, Antonio Llombart, Gilberto Luiz da Silva Amorim, J. Bines, Álvaro Rodríguez-Lescure, M Rodríguez de la Borbolla, Antonio Antón, J de la Haba, B Cardemil, E Garcia

Publikováno v: Cancer Research. 79:GS2-04

Background: Triple negative breast cancers (TNBC) have a greater risk of relapse than non-TNBC. New therapeutic approaches are needed for these patients (pts). CIBOMA/2004-01_GEICAM/2003-11 is a multinational, randomized phase III trial exploring adj

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b0aebf64b3256301578ee24865dcc030
https://doi.org/10.1158/1538-7445.sabcs18-gs2-04

Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry)

Autor: Norberto Batista, Ana Santaballa, Begoña Bermejo, José A. García-Sáenz, Lourdes Calvo, Angel Guerrero-Zotano, Marina Pollán, Purificación Martínez, J. M. López-Vega, Antonio J. Fernández, Miguel Martin, Juan de la Haba, Sara López-Tarruella, Antonio Llombart-Cussac, Emilio Alba, Raquel Andrés, Carlos Jara, Antonio Antón, Eva Carrasco, M. J. Escudero, Ainhara Lahuerta

Publikováno v: Sci Rep . 2019 Dec 27;9(1):20081
UCrea Repositorio Abierto de la Universidad de Cantabria
Universidad de Cantabria (UC)
Zaguán. Repositorio Digital de la Universidad de Zaragoza
instname
Scientific Reports
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
SCIENTIFIC REPORTS
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Repisalud
Instituto de Salud Carlos III (ISCIII)
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-FISABIO. Repositorio Institucional de Producción Científica

The debate about surgical resection of primary tumor (PT) in de novo metastatic breast cancer (MBC) patients persists. We explored this approach's outcomes in patients included in a retrospective registry, named El Álamo, of breast cancer patients d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e8df95d1a5c2724658eaae2761df5ac
https://hdl.handle.net/20.500.12105/8877

Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study

Autor: Nuria Ribelles, Sara Benito, Sonia Pernas, Ander Urruticoechea, Rosalia Caballero, Juan Carlos Montero, Silvia Antolín, Javier Orlando, Atanasio Pandiella, Eva Carrasco, Alejandro Falcon, M. J. Escudero, Alberto Ocaña, Federico Rojo, Alvaro Montaño, María Atienza, M. Gil-Martin, Manuel Ruiz-Borrego

Publikováno v: Digital.CSIC. Repositorio Institucional del CSIC
instname

[Background]: An important proportion of HER2-positive metastatic breast cancer patients do not respond to trastuzumab. The combination of dasatinib and trastuzumab has shown to be synergistic in preclinical models.
[Methods]: We conducted a pha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae4e5e7763a60366c781c8859eecd331
https://pubmed.ncbi.nlm.nih.gov/30607629